Striking the right balance between value and price in pharmaceuticals

SDA Bocconi Insight - Zoom On - C. Jommi


Last summer, Decree 9 of August 2019 was published in the Official Gazette, which revised the system for regulating drug pricing in Italy (Price Decree). The Italian Drug Agency (AIFA) held a public consultation, which wrapped up in September, to discuss guidelines consequent to the new legislative initiative during which drug companies submitted documentation to substantiate requests on eligibility for reimbursement and prices of their products. CERGAS (the Italian Research Center for Healthcare Management) at SDA Bocconi School of Management participated in this public consultation with a document in which, in addition to offering certain technical observations, underscored the importance of making decisions based on a structured and reproducible assessment of the value of new pharmaceuticals.



Related News

01 December 2020
OASI Report: 21 February, 2020, the Day That ...
OASI Report: 21 February, 2020, the Day That Changed the Italian Healthcare System
Learn More
24 November 2020
Lecci: data, governance and performance to ...
Lecci: data, governance and performance to face the emergency in Calabria
EMMAS Director at the Parliament’s Social Affairs Commission
Learn More

Related Programs